Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Breast cancer in systemic lupus erythematosus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.

METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.

RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.

CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

OriginalsprogEngelsk
TidsskriftOncology
Vol/bind93
Udgave nummer3
Sider (fra-til)191-196
Antal sider6
ISSN0030-2414
DOI
StatusUdgivet - 2017

ID: 52652178